Literature DB >> 26778127

Role of hypothalamic cannabinoid receptors in post-stroke depression in rats.

Shanshan Wang1, Hong Sun2, Sainan Liu2, Ting Wang2, Jinqun Guan2, Jianjun Jia3.   

Abstract

One of the most common psychological consequences of stroke is post-stroke depression (PSD). While more than 30 percent of stroke patients eventually develop PSD, the neurobiological mechanisms underlying such a phenomenon have not been well investigated. Given the critical involvement of hypothalamic-pituitary-adrenal axis and endocannabinoid system in response to stressful stimuli, we evaluated the hypothesis that cannabinoid receptors in the hypothalamus are critical for modulation of post-stroke depression-like behaviors in rats. To this end, rats were treated with middle cerebral artery occlusion (MCAO) followed by chronic unpredictable mild stress (CUMS) treatment procedure. We then assessed the expression of CB1 and CB2 receptors in the hypothalamus, and evaluated the effects of pharmacological stimulations of CB1 or CB2 receptors on the expression and development of depression-like behaviors in PSD rats. We found that PSD rats exhibited decreased the expression of CB1 receptor, but not CB2 receptor, in the ventral medial hypothalamus (VMH). Such an effect was not observed in the dorsally adjacent brain regions. Furthermore, intra-VMH injections of CB2 receptor agonist, but not CB1 receptor agonist, attenuated the expression of depression-like behaviors in PSD rats. Finally, repeated intraperitoneal injections of CB1 or CB2 receptor agonists during CUMS treatment inhibited the development of depression-like behaviors in PSD rats. Taken together, these results suggest that decreased CB1 receptor expression is likely associated with the development of post-stroke depression, and CB2 receptor may be a potential therapeutic target for the treatment post-stroke depressive disorders.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabinoid receptor; Chronic unpredictable mild stress; Hypothalamus; Middle cerebral artery occlusion; Post-stroke depression

Mesh:

Substances:

Year:  2016        PMID: 26778127     DOI: 10.1016/j.brainresbull.2016.01.006

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

1.  Ameliorative effect of Xiaoyao-jieyu-san on post-stroke depression and its potential mechanisms.

Authors:  Changde Wang; Chunlan Wu; Zhenguo Yan; Xiao Cheng
Journal:  J Nat Med       Date:  2018-09-07       Impact factor: 2.343

2.  Alteration of Glycerophospholipid Metabolism in Hippocampus of Post-stroke Depression Rats.

Authors:  Wenxia Jiang; Jianjun Chen; Lei Gong; Fang Liu; Huan Zhao; Jun Mu
Journal:  Neurochem Res       Date:  2022-04-25       Impact factor: 3.996

Review 3.  Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

Authors:  Uri Bright; Irit Akirav
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

4.  The antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a preclinical systematic review and meta-analysis.

Authors:  Noa Reuveni; Cole A Carlson; Sarah Schwartz; Diana Meter; Tyson S Barrett; Sara M Freeman
Journal:  Transl Psychiatry       Date:  2022-05-31       Impact factor: 7.989

Review 5.  Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.

Authors:  William E Fantegrossi; Catheryn D Wilson; Michael D Berquist
Journal:  Drug Metab Rev       Date:  2018-01-31       Impact factor: 4.518

6.  A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats with Post-Stroke Depression.

Authors:  Ce Chen; Yingying Dong; Fei Liu; Chengge Gao; Cui Ji; Yonghui Dang; Xiancang Ma; Yong Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-04       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.